FDA Should Ease Off-Label Regs Before Courts Do: PhRMA GC
The U.S. Food and Drug Administration can reduce the odds of a sweeping court decision that shields drugmaker promotion if it takes modest steps to relax restrictions on commercial speech about...To view the full article, register now.
Already a subscriber? Click here to view full article